Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial
PaperCitations, authors & open-access status
Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 308 citations, 2023 year and green oa status.
308
Citations
2023
Year
green
OA Status